M Eyerozyma Guilliermondii Species Complex: Review of Current Epidemiology, Antifungal Resistance, and Mechanisms Publisher Pubmed



Ghasemi R¹ ; Lotfali E² ; Rezaei K¹ ; Madinehzad SA¹ ; Tafti MF¹ ; Aliabadi N³ ; Kouhsari E^{4, 5} ; Fattahi M⁶
Source: Brazilian Journal of Microbiology Published:2022

Abstract

Meyerozyma guilliermondii has been accepted as a complex composed of Meyerozyma guilliermondii, Meyerozyma carpophila, and Meyerozyma caribbica. M. guilliermondii is a saprophyte detected on human mucosa and skin. It can lead to serious infections in patients with risk factors like chemotherapy, immunodeficiency, gastrointestinal or cardiovascular surgery, and oncology disorders. Most deaths related to M. guilliermondii infections occur in individuals with malignancy. In recent decades, incidence of M. guilliermondii infections is increased. Sensitivity of this microorganism to conventional antifungals (e.g., amphotericin B, fluconazole, micafungin and anidulafungin) was reduced. Prophylactic and empirical uses of these drugs are linked to elevated minimal inhibitory concentrations (MICs) of M. guilliermondii. Drug resistance has concerned many researchers across the world. They are attempting to discover appropriate solution to combat this challenge. This study reviews the most important mechanisms of resistance to antifungals developed by in M. guilliermondii species complex. © 2022, The Author(s) under exclusive licence to Sociedade Brasileira de Microbiologia.